Neurology Alert – February 1, 2013
February 1, 2013
View Issues
-
Switching to a New Epilepsy Drug: Is New Always Better?
Based on the prior work of patrick kwan and martin brodie, The efectiveness of the first antiepileptic drug (AED) in new-onset epilepsy is nearly 50%. -
Myasthenic Antibodies and Disease Phenotype
Do the presence or absence of acetylcholine receptor (AchR)-binding antibodies (Abs) and muscle-specific kinase (MuSK) Abs correlate with disease phenotype in myasthenia gravis (MG)? -
A Trial of Intracranial Pressure Monitoring in Traumatic Brain Injury — What Do We Do Now?
Chesnut et al have performed the first randomized, controlled trial to evaluate the benefit of intracranial pressure (ICP) monitoring on outcome after severe traumatic brain injury (TBI). -
MRI to Visualize Progression in Parkinson’s Disease
Dr. Henchcliffe reports she is on the speakers bureau and advisory board for Allergan and Teva; speakers bureau for Boehringer-Ingelheim, GlaxoSmith-Kline, and Novartis; advisory board for Merz; and is a consultant for Gerson Lehman Group and Guidepoint Global. -
EEG and MRI Findings in Children with Febrile Status Epilepticus
Although many children with a first febrile seizure will have had a simple febrile seizure, a relatively common and benign childhood illness, a subset will present in febrile status epilepticus, the most severe in the spectrum of febrile seizures. -
Pharmacology Watch: FDA Approves Apixaban for Patients with Nonvalvular AF
In this issue: Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions. -
Clinical Briefs in Primary Care supplement